Amedica Corporation Appoints New Vice President of Business Development

SALT LAKE CITY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a biomaterial company focused on silicon nitride ceramics as a material platform to develop, manufacture and commercialize novel medical devices, is pleased to announce the appointment of Anan Natarajan as Vice President of Business Development, effective immediately.

In this new role, Mr. Natarajan will be responsible for expanding Amedica's strategic alliances and business developments through original equipment manufacturer (OEM) and private labeling partnerships.

With over 20 years of strategic marketing and business development experience commercializing market-leading orthopedic and surgical device innovations, Mr. Natarajan provides significant development and industry expertise to the Company. Prior to joining Amedica Corporation, he was the Managing Partner at N2 Business Development Group, a management consulting firm focused on business development and commercializing projects for disruptive orthopedic and surgical device technologies. He previously held senior marketing, product and business development roles within acquired divisions of DePuy Synthes, Johnson & Johnson, GE Healthcare, and Covidien. Mr. Natarajan received his Bachelor of Arts degree in Biology from Franklin and Marshall College and a Masters of Business Administration degree in Finance from Rutgers University Graduate School of Management. He has also completed graduate studies in Physiology toward a Master's of Science degree from Rutgers University Graduate School.

"As we continue to cultivate our OEM and private labeling relationships, we recognize a growing need within the organization to evaluate, structure and execute on these partnership opportunities," said Eric Olson, CEO and President of Amedica Corporation. "I am confident that Anan's extensive breadth of experience within the orthopedics space will be a tremendous asset to our team. We are excited to have him lead efforts focused on positioning silicon nitride as the biomaterial of choice and standard of care."

"I am very excited to join the Amedica team," commented Mr. Natarajan. "I see tremendous potential for the expanded use of Amedica's proprietary silicon nitride technology platform, especially within spinal and orthopedic applications. I look forward to also pursuing other applications in the total joint, dental, trauma and sports medicine markets that can further leverage silicon nitride's proven anti-infective and osteopromotive properties."

About Amedica Corporation

Amedica is a company focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

The Company's web site for news releases and other information is

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 31, 2014, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

CONTACT: Mike Houston Director of Investor Relations 801-839-3534

Source:Amedica Corporation